Department of Surgical Oncology, Jules Bordet Institute, Free University of Brussels (ULB), Brussels, Belgium.
Department of Nuclear Medicine, Jules Bordet Institute, Free University of Brussels (ULB), Brussels, Belgium.
J Surg Oncol. 2021 May;123(8):1773-1783. doi: 10.1002/jso.26466. Epub 2021 Mar 22.
The histological growth pattern (HGP) represents a strong prognostic factor in patients undergoing surgery for colorectal liver metastases (CRLM). We evaluated whether the combination of HGP with clinico-metabolic parameters could improve its prognostic value.
In a series of 108 patients undergoing resection of CRLM, the HGP of CRLM was scored according to international guidelines. Baseline clinico-metabolic clinical status was evaluated using a metabolic-Clinical Risk Score (mCRS), combining traditional Memorial Sloan Kettering-CRS parameters with the tumor-to-liver glucose uptake ratio as measured with Fluorodeoxyglucose/positron emission tomography.
In patients with desmoplastic HGP (DHGP) CRLM (20% of all patients), 5- and 10-years overall survival (OS) and disease free survival (DFS) were 66% and 43% and 37% and 24.5%, as compared with 35% and 21% and 11% and 11% in the non-DHGP group (p = 0.07 and 0.054). Among DHGP patients, those with a low-risk mCRS had improved postoperative outcomes, 5- and 10-years OS and DFS reaching 83.3% and 62.5% and 50% and 33%, as compared with 18% and 0% and 0% and 0% in high-risk mCRS patients (p = 0.007 and 0.003). In contrast, mCRS did not influence postoperative survivals in non-DHGP patients.
Combining the clinico-metabolic characteristics with the HGP may improve prognostication in patients undergoing surgery for CRLM.
组织学生长模式(HGP)是结直肠癌肝转移(CRLM)患者接受手术治疗的一个强有力的预后因素。我们评估了 HGP 与临床代谢参数的结合是否可以提高其预后价值。
在 108 例接受 CRLM 切除术的患者中,根据国际指南对 CRLM 的 HGP 进行评分。使用代谢-临床风险评分(mCRS)评估基线临床代谢临床状态,该评分结合了传统 Memorial Sloan Kettering-CRS 参数和氟脱氧葡萄糖/正电子发射断层扫描测量的肿瘤与肝脏葡萄糖摄取率。
在具有纤维组织增生型 HGP(DHGP)的 CRLM 患者(所有患者的 20%)中,5 年和 10 年总生存率(OS)和无病生存率(DFS)分别为 66%和 43%和 37%和 24.5%,而非 DHGP 组分别为 35%和 21%和 11%和 11%(p=0.07 和 0.054)。在 DHGP 患者中,mCRS 低风险的患者术后结局得到改善,5 年和 10 年 OS 和 DFS 分别达到 83.3%和 62.5%和 50%和 33%,而 mCRS 高风险的患者则分别为 18%和 0%和 0%和 0%(p=0.007 和 0.003)。相比之下,mCRS 并未影响非 DHGP 患者的术后生存。
将临床代谢特征与 HGP 相结合可以改善接受 CRLM 手术治疗的患者的预后。